Literature DB >> 1756532

Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy.

A Osterborg1, M Masucci, S Bergenbrant, G Holm, A K Lefvert, H Mellstedt.   

Abstract

Lymphocytes from two patients with multiple myeloma stage I and one patient with monoclonal gammopathy of undetermined significance were found to proliferate specifically in response to low concentrations of F(ab')2 fragments of the autologous M component. T cell clones isolated from repeatedly stimulated cultures bound specifically the autologous idiotype and proliferated after addition of soluble idiotype and exogenous interleukin-2. The majority of clones were CD8+ and showed negligible staining for CD4. Idiotype-binding clones could not be isolated from cultures of lymphocytes from a healthy control stimulated under the same conditions. The study provides support for the existence of idiotype-reactive T cells in monoclonal gammopathies. Such cells might have a regulatory role on the tumor cell clone and may be important for a future therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1756532     DOI: 10.1007/bf01742306

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

Review 1.  Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation.

Authors:  R G Lynch; J W Rohrer; B Odermatt; H M Gebel; J R Autry; R G Hoover
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  How T cells see antigen.

Authors:  H M Grey; A Sette; S Buus
Journal:  Sci Am       Date:  1989-11       Impact factor: 2.142

3.  Activation of specific T cell lines by the antigens avidin and myelin basic protein in the absence of antigen-presenting cells.

Authors:  D M Altmann; O Lider; D C Douek; I R Cohen
Journal:  Eur J Immunol       Date:  1987-11       Impact factor: 5.532

4.  Isolation of human blood monocytes with Nycodenz, a new non-ionic iodinated gradient medium.

Authors:  A Bøyum
Journal:  Scand J Immunol       Date:  1983-05       Impact factor: 3.487

5.  Anti-idiotypic regulation of IgA expression in myeloma cells.

Authors:  G L Milburn; R G Lynch
Journal:  Mol Immunol       Date:  1983-09       Impact factor: 4.407

Review 6.  Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications.

Authors:  H Mellstedt; G Holm; M Björkholm
Journal:  Adv Cancer Res       Date:  1984       Impact factor: 6.242

7.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

8.  Effect of interleukin-2 on the ex vivo growth of human myeloma cells.

Authors:  D Peest; I de Vries; R Hölscher; R Leo; H Deicher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 9.  Immunoglobulin-specific suppressor T cells.

Authors:  R G Lynch
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

10.  Antigen-specific helper T cells required for dominant idiotype expression are not H-2 restricted.

Authors:  K Bottomly; D E Mosier
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.

Authors:  R Hájek; A W Butch
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

Review 2.  Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Authors:  Q Yi; A Osterborg
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

3.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.